CAS: 82854-37-3; (2R,3R,4R,5R,6R)-6-(3,4-Dihydroxyphenethoxy)-5-Hydroxy-2-((((2R,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)Methyl)-4-(((2S,3R,4R,5R,6S)-3,4,5-Trihydroxy-6-Methyltetrahydro-2H-Pyran-2-yl)Oxy)Tetrahydro-2H-Pyran-3-Yl 3-(3,4-

该化合物是主要来自Echinacea工厂,特别是Echinacea Purpurea的酚类化合物,被归类为甘蓝,由与葡萄糖分子相连的咖啡酸味组成; 胆碱酯酶展示了一系列生物活动,包括抗氧化剂,抗炎和免疫性循环效应,有助于将其用于传统草药; 该化合物以其潜在的治疗特性而著称,特别是在加强免疫功能和防治呼吸道感染方面; 胆碱酯酶在水和有机溶剂中溶解,使其能适应各种药物和营养素的应用; 其稳定性和生物利用率受到诸如pH值和温度等因素的影响; 此外,研究继续探索其行动机制及其在健康和健康方面的潜在利益. 与许多自然化合物一样,由于剂量和个人健康状况不同,该化合物的功效和安全可以不同,需要进一步研究以充分了解其治疗潜力.

英文名称(2R,3R,4R,5R,6R)-6-(3,4-Dihydroxyphenethoxy)-5-Hydroxy-2-((((2R,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)Methyl)-4-(((2S,3R,4R,5R,6S)-3,4,5-Trihydroxy-6-Methyltetrahydro-2H-Pyran-2-yl)Oxy)Tetrahydro-2H-Pyran-3-Yl 3-(3,4-
中文名称松果菊苷
IUPAC名称(2R,3R,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-4-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-yl (E)-3-(3,4-dihydroxyphenyl)acrylate
其它别名.Beta.-D-Glucopyranoside, 2-(3,4-Dihydroxyphenyl)Ethyl O-6-Deoxy-.Alpha.-L-Mannopyranosyl-(1->3)-O-(.Beta.-D-Glucopyranosyl-(1->6))-, 4-(3-(3,4-Dihydroxyphenyl)-2-Propenoate); Echinacoside,(S)
CAS编号82854-37-3
MFCD编号:MFCD00075695
EINECS号:617-397-7
FDA UNII编号:I04O1DT48T
分子式:C35H46O20
分子量:786.73
产品CID: 1818614
产品分类有机原料 → 含氮基化合物

相似结构搜索
产品信息参考
InChIKey: FSBUXLDOLNLABB-ISAKITKMSA-N
FSBUXLDOLNLABB-ISAKITKMSA-N…
计算化学: 氢键受体数20.0氢键供体数12.0可旋转键数14.0

物理性质

沸点1062.7±65.0 °C at 760 mmHg
闪点327.9±27.8 °C
密度1.7±0.1 g/cm3
pKa:8.43±0.20(预测)
PSA:324.44
LogP:0.14
折射率1.698
蒸汽压0.0±0.3 mmHg at 25°C
溶解性DMSO:60.0(Max Conc. mg/mL);76.26(Max Conc. Mm) DMSO:Pbs (Ph 7.2) (1:9):0.1(Max Conc. mg/mL);0.13(Max Conc. Mm) DMF:30.0(Max Conc. mg/mL);38.13(Max Conc. Mm) Ethanol:52.5(Max Conc. mg/mL);66.73(Max Conc. Mm) Water:24.36(Max Conc. mg/mL);30.96(Max Conc. Mm)
外观形态白米色粉末
储存条件惰性气氛,2-8°C
产品应用该化合物用作内容确定,识别和药理实验;物证药理效应,包括肾脏阳化,反施用和增强免疫活动.

合成工艺路线路线简述

专利信息

专利号:US-2025231101-A1
优先权日:2024-01-11
标题 :Validation of natural matrices for therapeutic use on humans, animals and plants on bio-physical bases as an alternative to validation through chemically definable substances derived from said matrices by isolation and/or synthesis processes and also as an alternative to products comprising natural matrices validated on the basis of their traditional use
发明人：MERCATI VALENTINO; LUCCI JACOPO
权利人:BIOS THERAPY PHYSIOLOGICAL SYSTEMS FOR HEALTH S P A
摘要:The present invention relates to a new method for assessing acceptability ranges or cut-offs for the compliance validation of batches of products comprising or consisting of one or more natural matrix, wherein said products have an ascertained therapeutic or beneficial effect. The invention also relates to a new process for the compliance validation of one or more batches of said products.

专利号:IT-MI20071051-A1
优先权日:2007-05-24
标题:COMPOSITION FOR NATURAL AND / OR SYNTHESIS TREATMENT OF BACTERIAL OR VIRAL INFLAMMATORY DISEASES OF THE THROAT, WITH THE PRESENCE OF XEROSTOMY.

其他信息查阅

苏州润新生物科技有限公司

网址: http://www.neupharma.com
电话: 0512-62956991👤

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

第 1 / 1 页

现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Kearney J, Knutsen HK, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Thies F, Tsabouri S, Vinceti M, Bresson JL, Siani A. Anxiofit-1 and reduction of subthreshold and mild anxiety: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2020 Oct 22;18(10):e06264. doi: 10.2903/j.efsa.2020.6264.
2: Gai X, Lin P, He Y, Lu D, Li Z, Liang Y, Ma Y, Cairang N, Zuo M, Bao Y, Gazang Z, Wu X. Echinacoside prevents hypoxic pulmonary hypertension by regulating the pulmonary artery function. J Pharmacol Sci. 2020 Dec;144(4):237-244. doi: 10.1016/j.jphs.2020.09.002. Epub 2020 Sep 10.
209:112563. doi: 10.1016/j.ejmech.2020.112563. Epub ahead of print. 477(21):4167-4190. doi: 10.1042/BCJ20200462.

合成参考文献

摘要:Zhou et al, 2013
参考文献:10.1016/0031-9422(96)00322-6
摘要:Miyase T, Yamamoto R, Ueno A. Phenylethanoid glycosides from Stachys officinalis. Phytochemistry. 1996 Sep;43(2):475–9. doi: 10.1016/0031-9422(96)00322-6.
参考文献:10.1016/s0378-8741(01)00297-5
摘要:Mensah AY, Sampson J, Houghton PJ, Hylands PJ, Westbrook J, Dunn M, Hughes MA, Cherry GW. Effects of Buddleja globosa leaf and its constituents relevant to wound healing. J Ethnopharmacol. 2001 Oct;77(2-3):219–26. doi: 10.1016/s0378-8741(01)00297-5.
参考文献:10.3736/jcim20121215
摘要:Zhu M, Zhou M, Shi Y, Li WW. Effects of echinacoside on MPP(+)-induced mitochondrial fragmentation, mitophagy and cell apoptosis in SH-SY5Y cells. Zhong Xi Yi Jie He Xue Bao. 2012 Dec;10(12):1427–32. doi: 10.3736/jcim20121215.
参考文献:10.1016/j.phymed.2014.04.034
摘要:Dapas B, Dall'Acqua S, Bulla R, Agostinis C, Perissutti B, Invernizzi S, Grassi G, Voinovich D. Immunomodulation mediated by a herbal syrup containing a standardized Echinacea root extract: a pilot study in healthy human subjects on cytokine gene expression. Phytomedicine. 2014 Sep 25;21(11):1406–10. doi: 10.1016/j.phymed.2014.04.034.